卵巢癌中MDR1的表达及其临床意义.doc

《卵巢癌中MDR1的表达及其临床意义.doc》由会员上传分享，免费在线阅读，更多相关内容在工程资料-天天文库。

1、卵巢癌中MDR1的表达及其临床意义作者：梁川，吴绪峰,陈慧君单位：武汉大学中南医院妇瘤科【摘要】目的检测MDR1在卵巢癌中的表达并探讨其在卵巢癌化疗耐药中的作用。方法采用RTPCR复合定量技术对，40例卵巢癌、20例良性卵巢肿瘤、20例止常'卵巢纽织中MDR1的表达进行检测，分析其表达与临床病理特征及化疗疗效的相关性。结果卵巢癌中MDR1的表达显著高于止常纽及良性肿瘤纽.，且肿瘤分化程度越差其表达越高，P<0.05oMDR1在术前化疗纽中的阳性农达率显著高于术前未化疗纽.，P<0.05oMDRI阴性纽崽者的化疗反应率显著高于阳性组患者(70.6%比43.5%),PV0.

2、05,MDR1阴性对化疗有效的预测值为70.6%。结论MDRInJ能在卵巢癌获得性耐药的形成中发挥一定作用，MDR1的检测可能有助于卵巢癌化疗方案的制定，并成为预测化疗疗效的有用指标。【关键词】卵巢癌；多药耐药基因；逆转录聚合酶链反应ExpressionofMultidmgResistanceGeneinEpithelialOvarianCarcinomaandItsClinicalSignificanceLIANGChuan,WUXufeng,CHENHuijunGynecologicOncologyDepartmentofZhongnanHospital,WuhanUniver

3、sity,Wuhan430071,ChinaCorrespondingAuthor:WuXufeng,Email：wuxuteng@371.netAbstract:ObjectiveTodetecttheexpressionofmultidrugresistancegene(MDRI)intheepithelialovariancarcinoma,andinvestigateitsroleindrugresistance・MethodsTheexpressionofMDRIin40casesofovariancarcinoma,20casesofbenignovariantumor

4、and20casesofnormalcontrolweredeterminedbyRTPCRtechnique・TherelationsbetweenMDRIexpressionandtheclinicalpathologicalcharacteristicsaswellaschemotherapeuticresponsewerediscussed.ResultsThepositiveexpressionrateofMDRIinovariancarcinomawassignificantlyhigherthanthatinbenigntumorsandnormaltissues,a

5、ndasignificantrelationshipwasshownbetweenitsexpressionandpathologicdifterentiation,P<0.05.TheMDRIpositiveexpressionrateincasesreceivedchemotherapybeforesurgeryweresignificantlyhigherthanincaseswhodidn't,P<0.05・TheresponserateintheMDRInegativegroupwashigherthanthatinthepositivegroup(70.6%

6、vs43.5%),P<0.05・ThepredictivevalueofnegativeMDRIstainingforobjectiveresponsewas70.6%.ConclusionThesedatasuggestedthatMDRImayplayanimportantroleintheacquiredmultidmgresistanceofovariancarcinoma.DetenninationofMDRIexpressionmaybeusefultorworkingoutchemotherapyplanandpredictingchemotherapeutic

7、responseofovariancarcinomapatients.Keywords：Ovariancarcinoma;Multidrugresistancegene;Reversetranscriptionpolymerasechainreaction加然卵巢癌对化疗相对敏感，但其远期效果并不理想，据报道尽管卵巢癌首次化疗有效率高达76%,但复发后降至20%[1],药物耐受是化疗失败的重要原因。肿瘤耐药的产生是多基因参与的复杂过程，其中以多药耐药基因MDRI(mu